Related Experiment Video
Updated: Jan 19, 2026
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Antje Tunger1,2, Ulrich Sommer3, Rebekka Wehner4,5
1National Center for Tumor Diseases (NCT), University Hospital Carl Gustav Carus, TU Dresden, Fetscherstraße 74, 01307 Dresden, Germany. antje.tunger@uniklinikum-dresden.de.
Abstract:
The administration of antibodies blocking the immune checkpoint molecules programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) has evolved as a very promising treatment option for cancer patients. PD-1/PD-L1 inhibition has significantly enhanced expansion, cytokine secretion, and cytotoxic activity of CD4+ and CD8+ T lymphocytes, resulting in enhanced antitumor responses. Anti-PD-1 or anti-PD-L1 therapy has induced tumor regression and improved clinical outcome in patients with different tumor entities, including melanoma, non-small-cell lung cancer, and renal cell carcinoma. These findings led to the approval of various anti-PD-1 or anti-PD-L1 antibodies for the treatment of tumor patients. However, the majority of patients have failed to respond to this treatment modality. Comprehensive immune monitoring of clinical trials led to the identification of potential biomarkers distinguishing between responders and non-responders, the discovery of modes of treatment resistance, and the design of improved immunotherapeutic strategies. In this review article, we summarize the evolving landscape of biomarkers for anti-PD-1 or anti-PD-L1 therapy.
Insights
Immune checkpoint inhibitors like anti-PD-1/PD-L1 therapies show promise in cancer treatment by boosting T cell activity. However, many patients don't respond, highlighting the need for predictive biomarkers.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) represent a significant advancement in cancer therapy.
- These therapies enhance T lymphocyte function, leading to improved antitumor responses and clinical outcomes in various cancers like melanoma and lung cancer.
- Despite successes, a substantial proportion of patients do not respond to PD-1/PD-L1 blockade, necessitating further research into treatment resistance.
Purpose of the Study:
- To review the current landscape of biomarkers associated with anti-PD-1 or anti-PD-L1 therapy.
- To explore how immune monitoring in clinical trials has identified factors differentiating responders from non-responders.
- To discuss the discovery of mechanisms underlying treatment resistance and inform the development of novel immunotherapeutic strategies.
Main Methods:
- Review of clinical trial data and published literature on immune checkpoint inhibitor therapy.
- Analysis of immune monitoring studies to identify potential predictive biomarkers.
- Synthesis of findings related to treatment resistance mechanisms and therapeutic strategies.
Main Results:
- PD-1/PD-L1 inhibition effectively boosts T cell responses and has led to approved therapies for several cancer types.
- Biomarker discovery through immune monitoring has begun to distinguish patient responses to these immunotherapies.
- Understanding resistance mechanisms is crucial for improving patient outcomes and designing next-generation treatments.
Conclusions:
- Biomarkers are essential for optimizing the use of PD-1/PD-L1 inhibitors and improving patient selection.
- Continued research into biomarkers and resistance mechanisms will drive the development of more effective cancer immunotherapies.
- The identification and application of predictive biomarkers hold the key to maximizing the benefits of immune checkpoint blockade.
More Related Videos
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019